Evaluate the efficacy of intradermal tranexamic acid in melisma.

Objective: To evaluate the efficacy of intradermal tranexamic acid in melasma. Stduy Design: Cross-Sectional study. Setting: Out-patient Department of Dermatology at Dow University of Health Sciences. Period: January 2018 to June 2018. Material & Methods: Enrolling 73 patients the research was done on patients with resistant melasma. For this 0.2 ml tranexamic acid diluted in 0.8 ml normal saline was injected intradermally into the melasma lesion at 1 cm distance at every 2 weeks for 4 months and results were analysed by using the modified Melasma Area and Severity Index (MASI) at their first visit and then monthly with strict sun protection. A total of 73 patients were included in this study with age ranging from 22 years to 47 years. All of them had resistant melasma and had not taken any treatment for the last six months. Results: Out of 73 patient 10 (13.7%) patients had poor response, 48 (65.8%) patients had fair response, 14 (19.1%) patients had good responses and only 1 (1.4%) had excellent response. No significant side effects were observed. Out of 73 patients, 63 patients were satisfied with the treatment. Only 2 patients complained of redness over the affected area which subsided within a week without any intervention, no other side effects were noted. Conclusion: Intralesonal tranexamic acid is safe, effective and an affordable option in resistant melasma.